Synthetic Genomics Inc. Appoints Oliver Fetzer, Ph.D., MBA as Chief Executive Officer

J. Craig Venter, Ph.D., Co-founder and Former CEO, becomes Executive Chairman and Co-Chief Scientist

(LA JOLLA, CA) October 27, 2014- Synthetic Genomics, Inc. (SGI), a synthetic biology company commercializing genomic technologies to revolutionize several industries, today announced the appointment of Oliver Fetzer, Ph.D., MBA as the company’s new Chief Executive Officer (CEO). In his role as CEO Fetzer will also be a member of SGI’s Board of Directors. Founding CEO, J. Craig Venter, Ph.D., will remain actively involved in SGI as Executive Chairman and Co-Chief Scientist with Co-Founder, Hamilton Smith, M.D.

“I am excited to welcome Oliver as the new CEO of SGI,” said Dr. Venter. “His decades of proven biotechnology product development experience coupled with his scientific intellect and measured leadership style will help drive SGI’s continued upward trajectory. I look forward to working with Oliver and the executive team to continue to meet our goals of turning SGI’s science and technology into commercially viable and societal changing products.”

Dr. Venter is also Co-Founder and CEO of the company Human Longevity, Inc., and Founder, Chairman and CEO of the not-for-profit J. Craig Venter Institute.

“I am thrilled to become the CEO of Synthetic Genomics, a company that unites leading science with a strong platform to address some of the world’s pressing needs, and a proven track record of applying these capabilities in high profile partnerships,” said Dr. Fetzer. “I look forward to working with Craig and an exceptional team to fulfill SGI’s vision and to advance the company into commercialization.”

Dr. Fetzer will lead all aspects of SGI, including management of SGI’s three business units- SGI-DNA, Synthetic Genomics Vaccines, Inc. (SGVI), and Genovia Bio. Over the last several years, SGI has refined its business plan to leverage and deploy its core synthetic biology technologies in a variety of industries. One of the most important recent announcements for the company is the agreement with Lung Biotechnology, a subsidiary of United Therapeutics Corporation, to create humanized pig organs for transplantation. SGI has also expanded its algae programs to include important deals with Archer Daniels Midland Company in the Omega-3 nutritional products sector.

Dr. Fetzer comes to SGI from Cerulean Pharma Inc., a pharmaceutical company that develops nanoparticle drug conjugate oncology therapeutics, where he was President and CEO for five years. Under Dr. Fetzer’s leadership, Cerulean advanced from a pre-clinical platform company to become a publicly traded clinical development stage company with a pipeline of product candidates.

Prior to Cerulean Pharma, Dr. Fetzer served in variety of positions at Cubist Pharmaceuticals, Inc., including Senior Vice President, Corporate Development and Research & Development, Senior Vice President, Corporate Development and Chief Business Officer, and Senior Vice President, Business Development. Dr. Fetzer began his career in 1993 in various positions of increasing responsibility at the Boston Consulting Group (BCG), a global leading management consulting firm, including Consultant, Project Leader, Principal, Partner and Managing Director. Since 2005, Dr. Fetzer has served on the board of directors of Auxilium Pharmaceuticals, Inc., and since 2011, on the board of Tecan Group AG.

Dr. Fetzer received a B.S. in Biochemistry from the College of Charleston, his Ph.D. in Pharmaceutical Sciences from the Medical University of South Carolina, and an MBA from Carnegie Mellon University.

About Synthetic Genomics Inc. (SGI)

SGI is a privately-held company dedicated to developing and commercializing genomic-driven solutions to address a wide range of global challenges. The company is focused on several key commercialization programs including developing new synthetic DNA products, tools and instruments through its subsidiary, SGI-DNA; new and improved algae based food and nutritional products, and biofuels through its subsidiary Genovia Bio; and synthetically-derived vaccines and anti-microbials through Synthetic Genomic Vaccines Inc. (SGVI), a business unit co-founded with the J. Craig Venter Institute. The company is also developing clean water technologies using microbial fuel cells and is developing sustainable agricultural products through AgraCast, a company co-founded with Plenus S.A. de C.V. For more information go to: www.syntheticgenomics.com.

SGI Media Contact

Heather Kowalski
858-361-0466
hkowalski@syntheticgenomics.com

Avoca Signs Supply Agreement with Synthetic Genomics Inc to Become Domestic Source of Natural Astaxanthin

KEARNY, NJ and LA JOLLA, CA, JUNE 20, 2014 – Avoca, Inc., a division of Pharmachem Laboratories, Inc., has formed a supply agreement with Synthetic Genomics, Inc. (SGI), a privately held company developing and commercializing genomic driven solutions and products in a variety of industries, to extract and commercialize natural astaxanthin from a strain of algae developed by SGI. The multi-year supply agreement also provides Avoca with exclusivity for product sales in North America. Pharmachem Laboratories will be responsible for marketing and sales. SGI is developing this product through their Genovia Bio business unit, which is responsible for the development and commercialization of algal-based food, chemical and fuel products. Financial details were not disclosed.

According to David Peele, President of Avoca, “This agreement will make us one of just a handful of vertically integrated, domestic producers of astaxanthin, with SGI providing sufficient algae biomass to ensure our customers of a consistent supply from U.S. sources,” said Peele. “Using their proprietary technology, SGI has developed algae with a higher level of astaxanthin, and as a result, we can provide 7.5% astaxanthin oleoresin with the concentration increasing over time as the algae strain and production technology is improved.”

“We are very pleased to enter into this agreement with Avoca,” said Jon Getzinger, Sr. Vice President, SGI. “Our ability to develop advantaged nutraceutical and human and animal feed ingredients coupled with Avoca’s ability to process and market those products, makes this an ideal agreement for both companies. Commercialization of astaxanthin with Avoca demonstrates how we can supply important high quality, natural ingredients to the market using our algae technology,” said Getzinger.

Natural astaxanthin is a supplement with multiple clinically-proven health benefits associated with its powerful antioxidant and anti-inflammatory properties. Natural astaxanthin is very difficult to produce and therefore is supply constrained relative to demand. SGI has developed a process for production of natural astaxanthin from a phototrophic source and demonstrated commercial-scale manufacturing capability and performance over 18 months. SGI’s natural astaxanthin has U.S. Food and Drug Administration regulatory approval for dietary supplement applications.

“We looked at several companies to partner with on this important ingredient,” said Jim Flatt, President of SGI’s Genovia Bio. “Avoca is the strong partner we sought who was capable of both processing high quality oil and delivering the product to the market through Pharmachem’s professional sales and marketing organization. Genovia Bio has rapidly developed two commercially-ready products, one each from heterotrophic (sugar-utilizing) and phototrophic (light-utilizing) algae, which distinguishes Genovia Bio in this field. It’s exciting to see the pipeline of products emerging from our investment in algae product technology.”

About Synthetic Genomics Inc. (SGI)

SGI is a privately-held company dedicated to developing and commercializing genomic-driven solutions to address a wide range of global challenges. The company is focused on several key commercialization programs including: developing new synthetic DNA products and technologies through its subsidiary, SGI-DNA; algae biofuels and new and improved food and nutritional products through its subsidiary Genovia Bio; and synthetically-derived vaccine development through Synthetic Genomic Vaccines Inc. (SGVI), a business unit co-founded with the J. Craig Venter Institute. The company is also developing clean water technologies using microbial fuel cells and is developing sustainable agricultural products through AgraCast, a company co-founded with Plenus S.A. de C.V. For more information go to www.syntheticgenomics.com.

About Pharmachem Laboratories, Inc.

Pharmachem Laboratories, Inc., Kearny, NJ, is a family of companies specializing in the manufacture and supply of a wide variety of custom and specialty nutritional ingredients, as well as process services. The company is a NOP-Certified organic handler and processor, operating 16 manufacturing facilities in the U.S. and Mexico. It is also (c)GMP compliant, producing a variety of ingredients and ingredient systems under strict quality control. For further information call 800-526-0609, 201-246-1000 (outside the U.S.) or visit www.pharmachemlabs.com.

Media Contact for SGI

Heather Kowalski
858-361-0466
hkowalski@syntheticgenomics.com

Technical/Scientific
Jon Getzinger
858-754-2960
jgetzinger@syntheticgenomics.com

Media Contact for Avoca

Tom McCartney
412-361-5178
tmcom@verizon.net

Synthetic Genomics Inc. and ADM Announce Omega-3 DHA Strategic Partnership

LA JOLLA, Calif. and DECATUR, Ill, May 19, 2014 – Synthetic Genomics Inc. (SGI), a privately held company developing and commercializing genomic driven advancements in a variety of industries, and Archer Daniels Midland Company (NYSE: ADM) announced today that the two companies have entered into a long-term agreement to commercialize Omega-3 Docosahexaenoic Acid (DHA) from algae. As part of the agreement, Omega-3 DHA will be produced and marketed throughout the world by ADM’s Foods & Wellness and Animal Nutrition groups. Financial details of the deal were not disclosed.

DHA is a long-chain omega-3 fatty acid that has been studied for its role in brain, heart and eye health. While it is typically found in fish and seafood products, extracting DHA directly from algae grown in fermentation tanks yields a highly purified form of DHA, which can then be used as a dietary supplement for humans and in animal feed.

“We are pleased to be working with ADM, a global leader in human and animal health and nutrition,” said J. Craig Venter, Founder and CEO, SGI. “This agreement is a major accomplishment for SGI as it represents commercial validation of our science and technology. We are eager to continue to work with ADM to develop other unique and nutritionally sound food and nutraceutical ingredients.”

“This partnership is an important example of ADM’s ongoing efforts to enhance returns by strengthening our portfolio of higher-margin products,” said Greg Dodson, general manager, ADM Foods & Wellness. “There is significant demand for Omega-3 DHA products. We are impressed with the leading edge technologies that SGI uses to quickly turn commercial opportunities into realities, and we look forward to working with them to use those capabilities to further enhance our current portfolio of nutritional ingredients.”

“The ADM partnership with SGI will prove beneficial for both companies by capitalizing on the strengths of SGI’s technologies and know-how, while using ADM’s significant scale and production capabilities to commercialize important products demanded by our customers,” said Brent Fenton, president, ADM Animal Nutrition. “The end result will be an improved animal nutrition portfolio, which will deliver value both to our customers and our shareholders.”

“We are excited to have this partnership with ADM that will allow them to provide a real alternative to what had been a very short list of non-fish derived DHA ingredients,” said Jon Getzinger, senior vice president at SGI. “Having a real choice in the market will provide manufacturers the opportunity for broader inclusion of this essential nutrient in food, beverage, nutraceutical and animal feed applications.”

The program will be done by SGI’s Genovia Bio business unit, leading producers of algal bio-based food, chemical, and fuel products. The team designs, develops, manufactures and enables others to manufacture nutritional and personal care ingredients, chemicals and fuels through low-cost, sustainable bio-based production methods from renewable feedstocks, including sugar, and carbon dioxide and sunlight. The business unit also licenses technology to strategic partners to manufacture higher-volume products.

Genovia Bio has labs within the SGI offices in La Jolla, California and has a research and development and phototrophic algae production facility in Calipatria, California near the Salton Sea.

About Synthetic Genomics Inc. (SGI)

SGI is a privately-held company dedicated to developing and commercializing genomic-driven solutions to address a wide range of global challenges. The company is focused on several key commercialization programs including: developing new synthetic DNA products and technologies through its subsidiary, SGI-DNA; algae biofuels and new and improved food and nutritional products through its subsidiary Genovia Bio; and synthetically-derived vaccine development through Synthetic Genomic Vaccines Inc. (SGVI), a business unit co-founded with the J. Craig Venter Institute. The company is also developing clean water technologies using microbial fuel cells and is developing sustainable agricultural products through AgraCast, a company co-founded with Plenus S.A. de C.V. For more information go to www.syntheticgenomics.com.

About ADM Foods & Wellness

ADM’s Foods & Wellness group offers a range of innovative specialty ingredients and products for the beverage, meat, snack, bakery, cerdodeal, wellness and personal care markets. As a global market leader in food-grade proteins, ADM’s Foods & Wellness group also markets numerous health and nutrition products, lecithin, acidulants, hydrocolloids and polyols.

About ADM Animal Nutrition

ADM Animal Nutrition is a leading manufacturing, nutrition and marketing company, which offers a wide range of innovative products for the animal nutrition market. Known as a global leader in amino acids, ADM Animal Nutrition also offers consistent, high-quality feed products, supplements, premixes, custom ingredient blends and specialty feed ingredients designed to provide leading-edge solutions, enabling our customers to meet and optimize animal health and nutrition goals.

About ADM

For more than a century, the people of Archer Daniels Midland Company (NYSE: ADM) have transformed crops into products that serve vital needs. Today, 31,000 ADM employees around the globe convert oilseeds, corn, wheat and cocoa into products for food, animal feed, industrial and energy uses. With more than 270 processing plants, 470 crop procurement facilities, and the world’s premier crop transportation network, ADM helps connect the harvest to the home in more than 140 countries. For more information about ADM and its products, visit www.adm.com.

Media Contact for SGI

Heather Kowalski
858-361-0466
hkowalski@syntheticgenomics.com

Media Relations for ADM

Jackie Anderson
217-424-5413
media@adm.com

Synthetic Genomics Inc. Signs Collaborative Research and Development Agreement with Lung Biotechnology Inc., a Subsidiary of United Therapeutics Corporation, to Develop Humanized Pig Organs to Revolutionize Transplantation Field

Lung Biotechnology Also Makes $50M Equity Investment in SGI

LA JOLLA, CA and SILVER SPRING, MD (May 6, 2014) – Synthetic Genomics Inc. (SGI), a privately held company developing and commercializing genomic driven advancements in a variety of industries, and Lung Biotechnology Inc., a subsidiary of United Therapeutics Corporation (NASDAQ: UTHR), today announced they have entered into a multi-year research and development agreement to develop humanized pig organs using synthetic genomic advances. The collaboration will focus upon developing organs for human patients in need of transplantation, with an initial focus on lung diseases. As part of the agreement SGI will receive royalties and milestone incentives from the development and commercialization of the organs.

SGI is also announcing a $50 million equity investment by Lung Biotechnology. Additional financial details were not disclosed.

“We are pleased to be partnering with Lung Biotechnology and United Therapeutics to advance organ transplantation,” said J. Craig Venter, Ph.D., Founder and CEO, SGI. “We believe that our proprietary synthetic genomic tools and technologies, coupled with United Therapeutics’ knowledge and advances in regenerative medicine technologies and treatment of lung diseases, should enable us to develop humanized pig organs for safe and effective transplant into humans. We believe this is one of the most exciting and important programs ever undertaken in modern medical science.”

Martine Rothblatt, Ph.D., United Therapeutics Chairman and CEO, added, “Our new collaboration with Synthetic Genomics is huge for accelerating our efforts to cure end-stage lung disease. Our combined expertise should enable us to develop an unlimited supply of transplantable organs, potentially helping millions of patients who die from end-stage organ disease.”

Using unique DNA design, DNA synthesis and genome editing, as well as genome modification tools, SGI will develop engineered primary pig cells with modified genomes. This work will entail modification of a substantial number of genes at an unprecedented scale and efficiency. United Therapeutics will leverage its xenotransplantation expertise to implant these engineered cells, generating pig embryos which develop and are born with humanized lungs. With the science and technology advances made by the SGI team in recent years, the companies are striving to develop these new methods and advances to create organs that are safe and effective for use in humans.

In the United States alone, about 400,000 people die annually from various forms of lung disease including cancer, but scarcely 2,000 people are saved with a lung transplant and only about 2,000 are added to the transplant wait list annually. Not even 1% of deaths due to lung failure can be avoided due to the gross shortage of transplantable human lungs. Previous attempts to rectify this shortage with animal organs have failed due to genomic incompatibilities, especially with respect to immune and coagulation systems. The collaboration between Synthetic Genomics and Lung Biotechnology aims to eliminate these genomic incompatibilities.

About Synthetic Genomics Inc. (SGI)

SGI is a privately-held company dedicated to developing and commercializing genomic-driven solutions to address a wide range of global challenges. The company is focused on several key commercialization programs including: developing new synthetic DNA products and technologies through its subsidiary, SGI-DNA; algae biofuels and new and improved food and nutritional products through its subsidiary Genovia Bio; and synthetically-derived vaccine development through Synthetic Genomic Vaccines Inc. (SGVI), a business unit co-founded with the J. Craig Venter Institute. The company is also developing clean water technologies using microbial fuel cells and is developing sustainable agricultural products through AgraCast, a company co-founded with Plenus S.A. de C.V. For more information go to www.syntheticgenomics.com.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of unique products to address the unmet medical needs of patients with chronic and life-threatening conditions. The company is developing several technologies to increase the availability of transplantable lungs for patients. www.unither.com

Forward Looking Statements

Statements included in this press release that are not historical in nature are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, among others, expectations regarding the outcome of the collaborative efforts among Lung Biotechnology, United Therapeutics and Synthetic Genomics, including the expectations regarding milestone and royalty payments, and the ability of these companies to successfully develop humanized pig organs that are safe and effective for transplantation. These forward-looking statements are subject to certain risks and uncertainties, such as those described in United Therapeutics’ periodic reports filed with the Securities and Exchange Commission, that could cause actual results to differ materially from anticipated results. Consequently, such forward-looking statements are qualified by the cautionary statements, cautionary language and risk factors set forth in United Therapeutics’ periodic reports and documents filed with the Securities and Exchange Commission, including its most recent Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. United Therapeutics claims the protection of the safe harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. This information is being provided as of May 6, 2014, and neither United Therapeutics nor Synthetic Genomics assumes any obligation to update or revise the information contained in this press release whether as a result of new information, future events or any other reason.

Media Contact for SGI

Heather Kowalski
858-361-0466
hkowalski@syntheticgenomics.com

Media Contact for United Therapeutics

Andrew Fisher
202-483-7000
afisher@unither.com

Prepared Statement on the Supreme Court Human Gene Patent Ruling

J. Craig Venter, Ph.D., Founder and CEO, Synthetic Genomics Inc. and Founder and CEO, the J. Craig Venter Institute

“Today the United States Supreme Court ruled on the validity of BRAC1 and BRAC2 human gene patents stating that, ‘A naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated, but cDNA is patent eligible because it is not naturally occurring,’ is consistent with our views on gene patents and is one we support. This ruling is good news for the biotech industry as it clarifies the rules and reduces uncertainty.

The field of genomics and specifically synthetic genomics holds great promise for exciting new knowledge to be gained and important products to be developed. In the case of synthetic genomic science and technology, it is clear that these advances are a direct result of human intervention and human construction of DNA. These man-made genetic constructs are already being used to create new vaccines, biofuels and nutritional products. And the ability to protect this intellectual property is a necessary component of a vital and robust science and biotechnology industry.”

Media Contact

Heather Kowalski, hkowalski@syntheticgenomics.com or 858-361-0466.

Synthetic Genomics, Inc. Launched to Develop New Approaches to Biological Energy

Initial applications to focus on ethanol and hydrogen production

ROCKVILLE, MD – June 29, 2005 – Synthetic Genomics, Inc., a new company that will develop and commercialize synthetic biology, was launched today. The Company will engineer modular “cassette” based systems to execute specific functions using reprogrammed cells as bio-factories. Synthetic Genomics, Inc.’s initial focus will be on ethanol and hydrogen production. After leveraging enormous archives of genomic sequence data, the Company will integrate novel processes to design, build, and test desired outputs from synthetic organisms.

According to J. Craig Venter, Ph.D., founder, chairman and chief executive officer of the Company, “Rapid advances in high throughput DNA sequencing and synthesis, as well as high performance computing and bioinformatics, now enable us to synthesize novel photosynthetic and metabolic pathways. Using diverse sets of genes, including those from over 300 fully-sequenced genomes, will allow our new company to develop synthetic organisms for specific industrial applications.”

A host cell that has reduced and reoriented metabolic needs can generate biological energy applicable to a broad range of industrial fields including energy, industrial organic compounds, pharmaceuticals, CO2 sequestration, fine chemicals, and environmental remediation. “We are in an era of rapid advances in science and are beginning the transition from being able to not only read genetic code, but are now moving to the early stages of being able to write code,” said Dr. Venter.

Founder and president Juan Enriquez added, “Harnessing the power of synthetic biology can lead to alternative energy sources that may have a significant impact on energy markets. We need to rapidly develop non-petrochemical, cleaner burning fuels.”

Synthetic Genomics, Inc. will collaborate with and sponsor research at the J. Craig Venter Institute, a non-profit institution with approximately 200 staff and scientists with expertise in genomics, microbiology, human and evolutionary biology, bioinformatics, high throughput DNA sequencing, environmental biology, information technology, biological energy research, and synthetic biology.

“Our sequencing of the first genomes, including the human genome, set the stage for this next great phase in understanding biology, which will ultimately enable us to pursue applications that will improve the environment and transform several industries,” said founder, co-chief scientific officer and Nobel laureate Hamilton Smith, MD. “Our group of renowned synthetic biology researchers at the institute has already made significant advances, including the synthesis of the Phi-X174 bacteriophage genome.”

Drs. Venter and Smith have long been focused on the ethical issues surrounding synthetic biology. They, along with various institute and external researchers, initiated a comprehensive policy review with ethical and scientific leaders prior to conducting the first experiments. The Venter Institute also recently announced participation in a major new policy study that will explore the risks and benefits of synthetic genomics.

In addition to Dr. Venter and Mr. Enriquez, the other founders and management team at Synthetic Genomics include: Dr. Smith, executive vice president and co-chief scientific officer; and David Kiernan, MD, JD, executive vice president and general counsel.

About Synthetic Genomics Inc.

Synthetic Genomics Inc., a privately held company founded in 2005, is dedicated to developing and commercializing genomic-driven solutions to address global energy and environmental challenges. Advances in synthetic genomics present limitless applications in a variety of product areas including: energy, chemicals and pharmaceuticals. The company’s main research and business programs are focused on major bioenergy areas: designing advanced biofuels with superior properties compared to ethanol and biodiesel; harnessing photosynthetic organisms to produce value added products directly from sunlight and carbon dioxide; developing new biological solutions to increase production and/or recovery rates of subsurface hydrocarbons and developing high-yielding, more disease resistant and economic feedstocks. For more information, visit www.syntheticgenomics.com.